List view / Grid view
13 March 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration Microbiology Devices Panel of the Medical Devices Advisory Committee recommended unanimously that the benefits of the cobas HPV Test...
7 March 2014 | By Roche
Diagnostics division strengthens its position in the serology market and expands its immunoassay portfolio in infectious disease...
5 March 2014 | By Roche
Roche presented new data from the LUTE / VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma...
4 March 2014 | By Roche
Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...
3 March 2014 | By Roche
Roche announced that an independent data monitoring committee has recommended that the phase III METLung study be stopped due to a lack of clinically meaningful efficacy...
21 February 2014 | By Roche
New automated CINtec PLUS test improves the detection of cervical pre-cancer...
30 January 2014 | By Roche
Roche’s CEO Severin Schwan: “2013 was a very good year for Roche. We exceeded our financial targets with strong demand for our existing products and positive uptake of recently launched medicines and diagnostics...
21 January 2014 | By Roche
Roche announced that two phase III studies of its investigational medicine bitopertin (RG1678) in adults with persistent, predominant negative symptoms of schizophrenia failed to meet their primary endpoints...
20 December 2013 | By Roche
“This positive opinion from the CHMP is a step toward providing physicians and patients the flexibility to choose whether intravenous or subcutaneous RoActemra treatment..."
22 November 2013 | By Novo Nordisk
Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart...
20 November 2013 | By Roche
Kadcyla is indicated as a single agent for the treatment of adults with HER2-positive, unresectable locally advanced or metastatic breast cancer...
4 November 2013 | By Roche
Roche will make an upfront payment of CHF 35 million to Polyphor as well as payments upon reaching certain development...
26 October 2013 | By Just:: Health Communications
“These data show that RoActemra can continue to deliver meaningful improvements for people living with rheumatoid arthritis..."
In this PCR In-Depth Focus: Challenges for qRT-PCR in detecting / quantifying microRNA in vitro and in vivo; Emerging clinical applications of digital PCR; Workshop Preview: Advanced 3d cell based assays, preparation, analysis and troubleshooting...
14 October 2013 | By Roche
Investment to help meet rising demand for licensed biologics and expected pipeline growth...
